Thyrocare Reports Robust Q4FY26 Results - Revenue Up 20%, PAT Up 128%

Thyrocare Technologies Limited (hereinafter referred to as "Thyrocare" NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended March 31, 2026.

Thyrocare expanded it's tests portfolio with advanced allergy testing (250+ SKUs on the Phadia platform) and forayed into genomics with a state-of-the-art lab and launch of NIPT, alongside a phased expansion of it's test menu to deepen clinical offerings in precision diagnostics.

The company delivered a robust performance in Q4FY26 with consolidated revenue of ₹223.95 crore, registering a strong 20% year-on-year growth, led by continued momentum in the Pathology segment which grew 21% YoY. EBITDA rose by 31% YoY to ₹75.09 crore. Profit After Tax surged 128% YoY to ₹48.70 crore, underscoring the company's focus on profitable growth.

India's largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing 59.0 million tests up 29% year-on-year. The Pathology business maintained strong traction with franchise revenue up 21% and partnership revenue up 23% (normalised partnership revenue up by 32% after adjusting one off camp revenue in Q4FY-25) year-onyear.

Thyrocare's unwavering commitment to quality delivered Six Sigma excellence by reducing complaints to 3.1 per million (down 34% YoY) with ATAT at 3.43 hours from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark.

Thyrocare's expanded it's test portfolio with advanced allergy testing (250+SKUs on the Phadia platform) and entered genomics with a state-of-the-art lab and launch of Non-invasive Pre-Natal Testing (NIPT), alongside a phased expansion of its test menu to deepen clinical offerings in precision diagnostics.

For FY26, consolidated revenue grew 21% YoY to ₹829.04 crore. In the Pathology business, franchise revenue increased 18% YoY, while partnership revenue, grew 32% YoY. Test volumes reached 209.6 million for the year, marking a 23% YoY growth. Consolidated EBITDA rose 38% YoY to ₹262.04 crore, and Profit After Tax grew 81% YoY to ₹162.85 crore, underscoring sustained growth momentum and operating leverage.

"Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India" - Rahul Guha, MD & CEO, Thyrocare Technologies Ltd.

Shares of Thyrocare Technologies Limited was last trading in BSE at Rs. 485.45 as compared to the previous close of Rs. 468.60. The total number of shares traded during the day was 742594 in over 23049 trades.

The stock hit an intraday high of Rs. 526.10 and intraday low of 478.15. The net turnover during the day was Rs. 374153731.00.

Source : Equity Bulls

Keywords

ThyrocareTechnologies INE594H01019 HealthcareServices Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate